DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Prat A, De Angelis C, Pascual T. et al.
HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.
J Clin Oncol 2018;
36 (Suppl.) Abstr.. 509
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.